Skip to main content
. 2019 Jan 28;20(3):552. doi: 10.3390/ijms20030552
ADC
ADCC
ADCP
Antibody-drug conjugate
Antibody-dependent cellular cytotoxicity
Antibody-dependent cellular phagocytosis;
AML Acute myeloid leukemia
APC-H7 Allophycocyanine-Hilite®7
ASM Aggressive systemic mastocytosis
BM
BMMC
Bone marrow
Bone marrow mast cell
CAR Chimeric antigen receptor
CM Cutaneous mastocytosis
CR Complete remission
EMA European Medicines Agency
FDA US Food and Drug Administration
FITC Fluorescein isothiocyanate
ISM Indolent systemic mastocytosis
ISMMC Indolent systemic mastocytosis with MC-restricted KIT mutation
ISMML Indolent systemic mastocytosis with multilineal KIT-mutated
KIT Stem cell factor receptor
MC Mast cell
MCL Mast cell leukemia
MFI
ORR
Mean fluorescence intensity
Overall response rate
PacB Pacific blue
PacO Pacific orange
PE Phycoerythrin
PeCy7 Phycoerythrin-cyanine 7
PerCPCy5.5 Peridinin-chlorophyll protein-cyanine 5.5
PNA Peptide nucleic acid
REMA Spanish Network on Mastocytosis
SI Stain index
SM Systemic mastocytosis
SM-AHN Systemic mastocytosis with an associated clonal non-MC lineage disease
SSM Smoldering systemic mastocytosis
TKI Tyrosine-kinase inhibitor
WDSM Well-differentiated systemic mastocytosis
WHO World Health Organization